Lexicon Pharmaceuticals | LXRX - Les Charges D'Exploitation





Les Charges D'Exploitation Changement Date
Abbott USD 9.31B 104M 2026-03
Acadia Pharmaceuticals USD 272.68M 6.08M 2026-03
Agios Pharmaceuticals USD 130.77M 10.77M 2026-03
Akebia Therapeutics USD 63.08M 8.26M 2025-12
Alnylam Pharmaceuticals USD 898.54M 66.78M 2026-03
AstraZeneca USD 8.18B 4.35B 2026-03
BioMarin Pharmaceutical USD 636.56M 39.61M 2026-03
Coherus Biosciences USD 51.83M 2.48M 2025-12
Eli Lilly USD 10.02B 285M 2026-03
Esperion Therapeutics USD 83.21M 14.06M 2025-12
Halozyme Therapeutics USD 192.19M 18.88M 2026-03
Illumina USD 852M 51M 2026-03
Insmed USD 506.24M 7.31M 2026-03
Ironwood Pharmaceuticals USD 57.33M 8.63M 2024-12
J&J USD 17.44B 1.53B 2026-03
Lexicon Pharmaceuticals USD 20.27M 6.1M 2025-12
MacroGenics USD 21.2M 32.13M 2026-03
MannKind USD 110.9M 8.74M 2026-03
Merck USD 18.17B 8.01B 2026-03
Moderna USD 1.78B 242M 2026-03
Novartis USD 9.29B 507M 2026-03
PTC Therapeutics USD 226.66M 19.64M 2026-03
Puma Biotechnology USD 49.26M 3.2M 2024-06
Sarepta Therapeutics USD 372.37M 480.65M 2026-03
Thermo Fisher Scientific USD 9.09B 821M 2026-03
Ultragenyx Pharmaceutical USD 305M 16M 2026-03
United Therapeutics USD 5.9B 5.1B 2026-03
Vanda Pharmaceuticals USD -1.14B 1.6B 2025-12